“Latest Stem Cells News”

IntelliCell BioSciences filed its patent application with the US Patent office that will claim priority to its provisional US patent serial #61/427, 221 that was filed on December 27, 2010. The title of the patent application is Ultrasonic Cavitation Derived Stromal or Mesenchymal Vascular Extracts and Cells Derived Therefrom Obtained from Adipose Tissue and use Thereof. It covers the methods of manufacturing using ultrasonic cavitation to dissociate the fat cells and blood vessels contained within the adipose tissue, thereby obtaining multi-potent, mesenchymal or stromal vascular fractions for use in human subjects. These methods do not include the use of any exogenous dissociating enzymes such as collagenase and result in increased number of cells which constitute the multi-potent, mesenchymal or stromal vascular fractions (about ten folds greater than methods which use collagenase to isolate these cells).

Dr. Steven Victor, the inventor, and CEO of IntelliCell BioSciences commented “we are extremely excited to have filed this patent in the US and around the world. The use of ultrasonic cavitation allows physicians to use less than 60cc’s of adipose tissue (fat) to manufacture approximately a half billion to 1.4 billion stromal vascular fraction cells (SVF cells) within five to ten minutes. The use of sound and water allows this manufacturing method to be utilized by physicians in the US underneath FDA (PHS Act Section 361 1271.10 (a)) of the health bill passed by Congress in 2009.

This manufacturing method has significant cost and time advantages over any other method of producing SVF cells. These cells have been used around the world for conditions caused by inflammation, such as lower back pain, migraines, MS, autism, fibromyalgia, tinnitus, arthritis; tissue repair, such as growing cartilage for bone on bone knee repair; bone and gingival tissue (gum disease): cosmetic indications such as fat grafting, wrinkle removal and other cosmetic procedures. The success rate for these patients has been approximately 80% plus. We believe that the use of non-enzymatic SVF cell therapy will find its first applications in treating sports related injuries. We are proud to have numerous luminaries on our advisory board who are leaders in the sports medicine world. We anticipate significant revenues from the utilization of SVF cells from the various IntelliCell BioSciences Centers of Excellence in the year 2012.

Incoming search terms:

Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function

Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for the treatment of patients suffering from acute myocardial infarction.

In the APOLLO trial all patients were treated with standard-of-care and subsequently underwent an abdominal liposuction. Each patient’s adipose tissue was processed by the Celution® System where ADRCs were extracted, washed and concentrated into a syringe of clinical grade cells. Within 36 hours of the myocardial infarction and no longer than 24 hours after undergoing percutaneous coronary intervention, patients received an injection of either 20 million ADRCs (n=10) or a placebo (n=4).

Incoming search terms:

New Technology to Increase Efficacy of Adult Stem Cells in COPD Treatment

Entest BioMedical announced today it has filed a second patent application in the area of Chronic Obstructive Pulmonary Disease (COPD). This new patent application builds upon the Company’s previously filed COPD patent application and involves the use of photoceutical devices to target stem cells toward areas impacted by COPD in the lungs.

Steve Josephs, PhD, a Scientific Advisor to the Company stated “that by using photoceutical devices in treating COPD, it is believed stem cells can be focused on areas of the lungs where there is damage. Furthermore, being able to target specific areas and draw stem cells to those areas should produce greater efficacy in patient treatment outcomes. ”

David Koos, Chairman and CEO of Entest stated, “This new patent application we filed covers methods of enhancing our previously disclosed adult stem cell technologies in the treatment of COPD. It is our belief the use of photoceuticals devices coupled with adult stem cell therapy is a treatment model completely new and unique to addressing this terrible disease.”

Entest’s treatment approach for COPD is based on the development of easy-toimplement therapies involving the use of stem cells, and other cells found in the fat tissue of the patient. By incorporating photoceutical devices currently in use for other clinical treatments, this invention discloses methods of increasing the rate of cell homing, retention, and growth factor production in the lung.

from http://www.entestbio.com/latest-news/entest-biomedical-files-patent-application-for-selective-targeting-of-stem-cells-to-lung-using-photoceutical-devices.html

Incoming search terms:

In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.

mTeSR1 is a fully defined medium and is the most widely used feeder-independent method for culturing human pluripotent stem cells, with citations in more than 25 publications.

read more on http://www.reuters.com/article/pressRelease/idUS155006+14-Sep-2009+BW20090914

Incoming search terms:

At the base of the neck is located a reserve of stem cells that could revolutionize the fight against obesity and diabetes. These fat-burning stem cells are the mother cells of brown adipose tissue, and a study coordinated by Italian researcher Saverio Cinti of the Marches region Polytechnic Institute discovered them. The results of the study were presented at the European Obesity Congress in Amsterdam and published in Faseb Journal, the magazine of the Federation of American experimental biology societies.

“It is possible to cultivate these stem cells to grow brown adipose tissue that can be transplanted into individuals to treat serious cases of obesity or diabetes,” explained Cinti. We will be able to control excess weight gain with cold temperatures, in addition to diet and physical exercise: “cold temperatures stimulate brown adipose, and it is sufficient to maintain a temperature of 18 degrees Celsius in order to increase its function”.

- BROWN AND WHITE TISSUE: are the two components of adipose tissue, which is actually considered by scientists to be an organ. White fat accumulates fat cells and in the past has played a decisive role in helping humans tolerate long periods without food. Now it is mainly blamed for the dreaded ‘belly’. On the other hand, brown fat cells burn fat and consume glucose.

Brown fat is abundant in infants and until a short while ago, it was believed that this highly important reserve disappeared with age. Recent studies, some of which were conducted by Cinti’s group, have observed brown adipose reserves in adults. Now it has been discovered that there is a reserve of brown fat cells that exist in adults.

- FAT-BURNING STEM CELLS PRESENT IN ONE OUT OF THREE ADULTS: the discovery is based on tissue biopsies on 35 individuals who underwent thyroid operations. “We found brown adipose tissue stem cells in one-third of the patients. This result,” observed Cinti, “confirms statistical data showing that this tissue is highly present in young and thin individuals. Individuals who are not thin are probably born with less brown adipose tissue.”

- FAT-BURNING TISSUE FACTORIES: knowing where to find brown fat stem cells means being able to cultivate them in order to transplant them into patients affected by obesity or diabetes.

- ACTIVATING BROWN FAT STEM CELLS: is another strategy that is now becoming possible. Stimulating stem cells involves stimulating the growth of brown fat in order to activate a natural mechanism that burns fat.

- COLD TEMPERATURES BURN MORE FAT TISSUE: together with diet and physical exercise, cold temperatures are becoming an important ally to combat excess weight and obesity. Keeping a low temperature at home during the winter (around 18 degrees Celsius) or walking in the cold helps burn fat and glucose. Calculations show that 50 to 100 grams of brown fat tissue result in a loss of 4-5kg per year.

Incoming search terms:

Baldness is an undesirable condition that afflicts both men and women, many of which have family members with significant hair loss. According to Health Day News, a new study of stem cells in mice shows promise for future treatments for people who battle hair loss.

The study was conducted on the fatty skin layers of mice by researchers at Yale University. Specifically, adipose precursor cells were found to spur new hair growth in mice, according to Health Day News.

Stem cells are present in hair follicles, which help generate hair growth. Health Day News explains that these cells are still present in people with baldness, but the follicles no longer receive signals to grow new hair. At the same time, hair loss causes a decrease in natural fat cells within the scalp.

“If we can get these fat cells in the skin to talk to the dormant stem cells at the base of the hair follicles, we might be able to get hair to grow again,” said senior study author Valerie Horsley, as quoted by Health Day News.

Incoming search terms: